Chelating agents

Excel Diagnostics and Nuclear Oncology Center Announces FDA Authorization of IND for 225Ac-PSMA I&T Targeted Alpha Therapy for Castration Resistant Prostate Cancer

Retrieved on:

Mittwoch, August 4, 2021

Branches of biology, Health sciences, Chemistry, Radiopharmaceuticals, Orphan drugs, Chelating agents, Macrocycles, Glutamate carboxypeptidase II, Proteases, MCRPC, DOTA-TATE, Prostate cancer

Houston, TX, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Excel Diagnostics and Nuclear Oncology Center (EDNOC), a premier Diagnostic Imaging and Radioligand Therapy center in Houston, Texas announces approval of its physicians sponsored Investigational New Drug (IND) application for providing Targeted Alpha Therapy (TAT) with 225Ac-PSMA I&T for metastatic Castration-Resistant Prostate Cancer (mCRPC).

Key Points:

Houston, TX, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Excel Diagnostics and Nuclear Oncology Center (EDNOC), a premier Diagnostic Imaging and Radioligand Therapy center in Houston, Texas announces approval of its physicians sponsored Investigational New Drug (IND) application for providing Targeted Alpha Therapy (TAT) with 225Ac-PSMA I&T for metastatic Castration-Resistant Prostate Cancer (mCRPC).
Excel Diagnostics and Nuclear Oncology Center has been a pioneer in bringing new targeted Radioligand Therapies such as Lu-177 DOTATATE, and Lu-177 PSMA to serve our patients in the United States.
Highly encouraging results have been reported by using Targeted Alpha Therapy (TAT) Radiopharmaceuticals in conditions such as neuroendocrine, prostate, or hematological malignancies.
In April of 2020, Excel passed FDA inspection of one of its investigational drugs with no deficiencies or citations.

Moonstone Nutrition Launches Alkali Citrate Capsules for Kidney Health Support

Retrieved on:

Donnerstag, Juli 1, 2021

Chemical substances, Citrates, Food acidity regulators, Organ systems, Kidney diseases, Chelating agents, Acute pain, Kidney stone disease, Kidney, Chemistry, Citric acid

PITTSBURGH, July 1, 2021 /PRNewswire/ -- Moonstone Nutrition , a Pittsburgh-based startup, has added capsules to its kidney health product line.

Key Points:

PITTSBURGH, July 1, 2021 /PRNewswire/ -- Moonstone Nutrition , a Pittsburgh-based startup, has added capsules to its kidney health product line.
Moonstone's patented alkali citrate formula was created by top kidney doctors with ingredients known to prevent the formation of kidney stones.
In 2020 Moonstone's kidney stone experts launched an OTC line of ready-to-mix powder beverages with 30mEq of alkali citrate per serving.
Moonstone aims to raise awareness about the prevalence of kidney stones and the importance of overall kidney health.

Orphalan Announces Positive Top Line Data with Trientine Tetrahydrochloride for Maintenance Patients with Wilson’s Disease

Retrieved on:

Freitag, Juni 25, 2021

Health sciences, Chemistry, Chelating agents, Health, Ethyleneamines, Triethylenetetramine, Wilson's disease, Penicillamine, Therapy

Orphalan today announced positive top line results from a phase 3 head-to-head trial comparing d-Penicillamine with trientine tetrahydrochloride in Wilsons Disease (WD).

Key Points:

Orphalan today announced positive top line results from a phase 3 head-to-head trial comparing d-Penicillamine with trientine tetrahydrochloride in Wilsons Disease (WD).
Trientine tetrahydrochloride if approved has the potential to be used as maintenance therapy in patients with Wilsons Disease.
These top-line results suggest that trientine tetrahydrochloride offers a differentiated tolerability profile and represents a safe and effective alternative to d-Penicillamine as a maintenance therapy for patients with Wilsons Disease.
Trientine tetrahydrochloride is an investigational, novel oral trientine formulation with Orphan Drug Designation under development through a 505(b)(2) pathway for the treatment of Wilsons Disease maintenance patients.The trientine tetrahydrochloride NDA is planned to be submitted mid-year 2021.

2021 Global Tributyl Citrate (CAS 77-94-1) Market Research Report - Key Manufacturers and Distributors - ResearchAndMarkets.com

Retrieved on:

Freitag, Juni 11, 2021

Chemicals, Plastics, Manufacturing, Enzymes, Chemical substances, Citrates, Chelating agents, Food acidity regulators, Citric acid, Citrate (pro-3S)-lyase, Citrate (Re)-synthase

The "Tributyl citrate (CAS 77-94-1) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points:

The "Tributyl citrate (CAS 77-94-1) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.
This global report is a result of industry experts' diligent work on researching the world market of Tributyl citrate.
The Tributyl citrate global market report key points:
The first chapter introduces the product (composition, structure, hazards, storage, toxicological & ecological information, etc.).
The fifth chapter deals with Tributyl citrate market trends and forecast, distinguish Tributyl citrate manufacturers and suppliers.

RadioMedix & Curium Announce Detectnetᵀᴹ (copper Cu 64 dotatate injection) Inclusion on NCCN Guidelines®

Retrieved on:

Mittwoch, Mai 5, 2021

Branches of biology, Medical specialties, Organ systems, Radiopharmaceuticals, Orphan drugs, G protein-coupled receptors, Neuroendocrinology, Chelating agents, Somatostatin receptor 2, DOTA-TATE, Neuroendocrine tumor, Copper (64Cu) oxodotreotide

Louis, MO, May 05, 2021 (GLOBE NEWSWIRE) -- RadioMedix Inc. and its commercial partner Curium announced today that Detectnet is now included in the National Comprehensive Cancer Network\xc2\xae (NCCN) Clinical Practice Guidelines in Oncology \xe2\x80\x93 Neuroendocrine and Adrenal Tumors, version 1.2021 for the evaluation of neuroendocrine tumors (NETs).

Key Points:

Louis, MO, May 05, 2021 (GLOBE NEWSWIRE) -- RadioMedix Inc. and its commercial partner Curium announced today that Detectnet is now included in the National Comprehensive Cancer Network\xc2\xae (NCCN) Clinical Practice Guidelines in Oncology \xe2\x80\x93 Neuroendocrine and Adrenal Tumors, version 1.2021 for the evaluation of neuroendocrine tumors (NETs).
Effective April 1, 2021, all sites of care will use code A9592 to submit for reimbursement for all patients.
\xe2\x80\x9cThe Phase III results demonstrate the high sensitivity, specificity, and accuracy of Detectnet.
In published trials nausea immediately after injection was observed.\nNon-radioactive somatostatin analogs and copper Cu 64 dotatate competitively bind to somatostatin receptors (SSTR2).

RadioMedix & Curium Announce Detectnetᵀᴹ (copper Cu 64 dotatate injection) Inclusion on NCCN Guidelines®

Retrieved on:

Mittwoch, Mai 5, 2021

Louis, MO, May 05, 2021 (GLOBE NEWSWIRE) -- RadioMedix Inc. and its commercial partner Curium announced today that Detectnet is now included in the National Comprehensive Cancer Network\xc2\xae (NCCN) Clinical Practice Guidelines in Oncology \xe2\x80\x93 Neuroendocrine and Adrenal Tumors, version 1.2021 for the evaluation of neuroendocrine tumors (NETs).

Key Points:

Louis, MO, May 05, 2021 (GLOBE NEWSWIRE) -- RadioMedix Inc. and its commercial partner Curium announced today that Detectnet is now included in the National Comprehensive Cancer Network\xc2\xae (NCCN) Clinical Practice Guidelines in Oncology \xe2\x80\x93 Neuroendocrine and Adrenal Tumors, version 1.2021 for the evaluation of neuroendocrine tumors (NETs).
Effective April 1, 2021, all sites of care will use code A9592 to submit for reimbursement for all patients.
\xe2\x80\x9cThe Phase III results demonstrate the high sensitivity, specificity, and accuracy of Detectnet.
In published trials nausea immediately after injection was observed.\nNon-radioactive somatostatin analogs and copper Cu 64 dotatate competitively bind to somatostatin receptors (SSTR2).

RayzeBio Appoints Yi Larson to Its Board of Directors and Expands Team with Key Leadership Hires

Retrieved on:

Mittwoch, April 21, 2021

Biotechnology, Health, Radiology, Pharmaceutical, Oncology, Health sciences, Chelating agents, Macrocycles, Orphan drugs, Radiopharmaceuticals, Novartis, Life sciences, Chemistry, Lutetium (177Lu) oxodotreotide, XC2

b'RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, appointed Yi Larson to its board of directors effective April 1, 2021.

Key Points:

b'RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, appointed Yi Larson to its board of directors effective April 1, 2021.
\xe2\x80\x9cThe company has impressively built an infrastructure to drive innovation in the sector.
Prior to joining RayzeBio, Dan was the head of radiopharmaceutical manufacturing at Novartis/AAA for Lutathera\xc2\xae, an approved targeted radiotherapy drug.
\xe2\x80\x9cDerek and Dan have been working with RayzeBio since earlier this year and have contributed to tangible progress in our discovery and development efforts.

Global Sodium Citrate Market Procurement Intelligence Report with COVID-19 Impact Analysis | Global Market Forecasts, Analysis 2021-2025 | SpendEdge

Retrieved on:

Dienstag, April 13, 2021

Chemistry, Physical sciences, Chemical compounds, Chelating agents, Citrates, Supply chain management, Competition, Pricing, Sodium citrate, Sodium, Procurement

b"NEW YORK, April 13, 2021 /PRNewswire/ -- The Sodium Citratemarket will register an incremental spend of about USD 61.85 Million, growing at a CAGR of 3.73% during the five-year forecast period.

Key Points:

b"NEW YORK, April 13, 2021 /PRNewswire/ -- The Sodium Citratemarket will register an incremental spend of about USD 61.85 Million, growing at a CAGR of 3.73% during the five-year forecast period.
A targeted strategic approach to Sodium Citratesourcing can unlock several opportunities for buyers.
This report also offers market impact and new opportunities created due to the COVID-19 pandemic.
During the forecast period, the market expects a change of 5.00%-8.00%.\nExpected changes in price forecast and factors driving the current and future price changes.\nIdentify pricing models that offer the most rewarding opportunities.\nSome of the top Sodium Citrate suppliers listed in this report:\nThis Sodium Citrate procurement intelligence report has enlisted the top suppliers and their cost structures, SLA terms, best selection criteria, and negotiation strategies.\n"

RadioMedix & Curium Announce Simplified Coding for DetectnetTM (copper Cu 64 dotatate injection)

Retrieved on:

Dienstag, März 23, 2021

Orphan drugs, Radiopharmaceuticals, Branches of biology, Drugs, Medicine, G protein-coupled receptors, Chelating agents, Macrocycles, DOTA-TATE, Somatostatin receptor 2, Copper (64Cu) oxodotreotide, Somatostatin

Ensure safe handling and preparation procedures to protect patients and health care workers from unintentional radiation exposure.

Key Points:

Ensure safe handling and preparation procedures to protect patients and health care workers from unintentional radiation exposure.
The uptake of copper Cu 64 dotatate reflects the level of somatostatin receptor density in NETs, however, uptake can also be seen in a variety of other tumors that also express somatostatin receptors.
A negative scan after the administration of Detectnet in patients who do not have a history of NET disease does not rule out disease.
Non-radioactive somatostatin analogs and copper Cu 64 dotatate competitively bind to somatostatin receptors (SSTR2).

RadioMedix & Curium Announce Permanent HCPCS Code for DetectnetTM (copper Cu 64 dotatate injection)

Retrieved on:

Dienstag, Januar 26, 2021

Ensure safe handling and preparation procedures to protect patients and health care workers from unintentional radiation exposure.

Key Points:

Ensure safe handling and preparation procedures to protect patients and health care workers from unintentional radiation exposure.
The uptake of copper Cu 64 dotatate reflects the level of somatostatin receptor density in NETs, however, uptake can also be seen in a variety of other tumors that also express somatostatin receptors.
A negative scan after the administration of Detectnet in patients who do not have a history of NET disease does not rule out disease.
Non-radioactive somatostatin analogs and copper Cu 64 dotatate competitively bind to somatostatin receptors (SSTR2).